Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Glucagon-like peptide-1 (GLP-1) analogue Liraglutide effectively promotes preoperative weight loss in patients with severe obesity undergoing bariatric surgery. This treatment resulted in an average weight reduction of 5.50% over three months, improving surgical outcomes.
Area Of Science
- Metabolic Surgery
- Pharmacological Interventions
- Obesity Medicine
Background
- Preoperative weight loss is crucial for improving outcomes and reducing morbidity in bariatric surgery patients.
- Managing severe obesity presents challenges, necessitating effective weight management strategies before surgical intervention.
Purpose Of The Study
- To evaluate the efficacy of the GLP-1 analogue Liraglutide as a tool for preoperative weight loss in individuals with severe obesity.
- To assess the impact of Liraglutide on body composition and weight reduction in patients preparing for bariatric-metabolic surgery.
Main Methods
- A single-center, quasi-experimental prospective study involving 37 adult patients with a body-mass index (BMI) ≥ 48 kg/m².
- Participants received Liraglutide, with doses escalating weekly from 0.6 mg to 3.0 mg daily for 12 weeks.
- Weight loss and body composition were monitored monthly using bioelectrical impedance analysis.
Main Results
- The study included 37 participants (76% female, average age 44 years) with an average BMI of 56.04 kg/m².
- After 3 months of Liraglutide treatment, the average weight decreased from 147.4 kg to 139.3 kg, a total weight loss of 5.50%.
- 94.6% of patients experienced some degree of weight loss, with only 5.40% showing no change.
Conclusions
- Liraglutide demonstrates effectiveness as an adjuvant therapy for preoperative weight loss in patients with severe obesity.
- The use of Liraglutide can contribute to better outcomes and reduced complications associated with bariatric surgery.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...